Shilpa Medicare Ltd (BOM:530549)

Q2 2026 Shilpa Medicare Ltd Earnings Call Transcript

Nov 16, 2025 / 05:30 AM GMT

Release Date Price: ₹379.1 (-0.13%)

Transcript

Key Points

Positve

Shilpa Medicare Ltd (BOM:530549) recorded the highest quarterly EBITDA in the company's history, showcasing strong financial performance.
The company is experiencing growth in its API business, particularly in oncology and non-oncology segments, with new product filings in the US and Europe.
Shilpa Medicare Ltd is expanding its capacity for key products like tranexamic acid, with plans to commission additional capacity in the next financial year.
The formulation business division successfully launched its first NCE program in India, indicating progress in innovative product development.
The company reported a strong EBITDA margin of 30% for both the quarter and the first half, reflecting improved operational efficiency and profitability.

Negative

The company faces challenges with US FDA inspections, with no current updates on the status of their Jujla plant.
There is uncertainty regarding the commercialization timeline for some products, such as the OLC contract, which may impact future revenue projections.
The competitive landscape in the European oncology injectable market is intense, requiring a focus on complex generics and differentiated products to maintain market share.
Licensing income is variable and can be lopsided depending on the stage of product development, leading to potential fluctuations in revenue.
The company is late in entering the semaglutide market, which may affect its ability to capture significant market share despite its backward integration strategy.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SHME.NS - Shilpa Medicare Ltd
Q2 2026 Shilpa Medicare Ltd Earnings Call
Nov 17, 2025 / 05:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Shilpa Medicare Limited Q2 F 526 earnings conference call.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing and 0 on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Muni Shah, head of strategy and this relations.

Thank you and over to you, Mr. Shah.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.